Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2016

01-03-2016 | Original Article

Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice

Authors: Y. Zhang, L. Wang, Y. Song, X. Zhao, M. S. Wong, W. Zhang

Published in: Osteoporosis International | Issue 3/2016

Login to get access

Abstract

Summary

The skeletal renin-angiotensin system contributes to the development of osteoporosis. The renin inhibitor aliskiren exhibited beneficial effects on trabecular bone of osteoporotic mice, and this action might be mediated through angiotensin and bradykinin receptor pathways. This study implies the potential application of renin inhibitor in the management for postmenopausal osteoporosis.

Introduction

The skeletal renin-angiotensin system plays key role in the pathological process of osteoporosis. The present study is designed to elucidate the effect of renin inhibitor aliskiren on trabecular bone and its potential action mechanism in ovariectomized (OVX) mice.

Methods

The OVX mice were treated with low dose (5 mg/kg) or high dose (25 mg/kg) of aliskiren or its vehicle for 8 weeks. The bone turnover markers were measured by ELISA. The structural parameters of trabecular bone at lumbar vertebra (LV) and distal femoral metaphysis were measured by micro-CT. The expression of messenger RNA (mRNA) and protein was studied by RT-PCR and immunoblotting, respectively.

Results

Aliskiren treatment reduced urinary excretion of calcium and serum level of tartrate-resistant acid phosphatase in OVX mice. The treatment with aliskiren significantly increased bone volume (BV/TV) and connectivity density (Conn.D) of trabecular bone at LV-2 and LV-5 as well as dramatically enhanced BV/TV, Conn.D, bone mineral density (BMD/BV) and decreased bone surface (BS/BV) at the distal femoral end. Aliskiren significantly down-regulated the expression of angiotensinogen, angiotensin II (Ang II), Ang II type 1 receptor, bradykinin receptor (BR)-1, and osteocytic-specific gene sclerostin as well as the osteoclast-specific genes, including carbonic anhydrase II, matrix metalloproteinase-9, and cathepsin K.

Conclusions

This study revealed that renin inhibitor aliskiren exhibited the beneficial effects on trabecular bone of ovariectomy-induced osteoporotic mice, and the underlying mechanism for this action might be mediated through Ang II and BR signaling pathways in bone.
Literature
1.
Namazi S, Ardeshir-Rouhani-Fard S, Abedtash H (2011) The effect of renin angiotensin system on tamoxifen resistance. Med Hypotheses 77:152–155CrossRefPubMed
2.
Skov J, Persson F, Frøkiær J, Christiansen JS (2014) Tissue renin-angiotensin systems: a unifying hypothesis of metabolic disease. Front Endocrinol 5:23CrossRef
3.
Lau T, Carlsson PO, Leung PS (2004) Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47:240–248CrossRefPubMed
4.
Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC (2008) Combination therapy with AT1 receptor blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Proc Natl Acad Sci U S A 105:15896–15901CrossRefPubMedPubMedCentral
5.
Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, Chen Y, Zhang Z, Strugnell S, Sabbagh Y, Arbeeny C, Li YC (2009) Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 297:F791–F801CrossRefPubMedPubMedCentral
6.
Koïtka A, Cao Z, Koh P, Watson AMD, Sourris KC, Loufrani L, Soro-Paavonen A, Walther T, Woollard KJ, Jandeleit-Dahm KA, Cooper ME, Allen TJ (2010) Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia 53:584–592CrossRefPubMed
7.
Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M (2011) Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens 29:2236–2245CrossRefPubMed
8.
Naffah-Mazzacoratti Mda G, Gouveia TL, Simões PS, Perosa SR (2014) What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders? World J Biol Chem 5:130–140PubMed
9.
Herr D, Bekes I, Wulff C (2013) Local renin-angiotensin system in the reproductive system. Front Endocrinol 4:150CrossRef
10.
Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, Nimura Y, Ishida J, Fukamizu A, Ikeda K (2009) Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24:241–250CrossRefPubMed
11.
Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, Inagami T, Ezura Y, Noda M (2009) Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem 284:4857–4864CrossRefPubMed
12.
Lamparter S, Kling L, Schrader M, Ziegler R, Pfeilschifter J (1998) Effects of angiotensin II on bone cells in vitro. J Cell Physiol 175:89–98CrossRefPubMed
13.
Kumar R, Boim MA (2009) Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 18:33–39CrossRefPubMed
14.
Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465–2475CrossRefPubMed
15.
Hiruma Y, Inoue A, Hirose S, Hagiwara H (1997) Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun 230:176–178CrossRefPubMed
16.
Kaneko K, Ito M, Fumoto T, Fukuhara R, Ishida J, Fukamizu A, Ikeda K (2011) Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res 26:2959–2966CrossRefPubMed
17.
Gu SS, Zhang Y, Li XL, Wu SY, Diao TY, Hai R, Deng H (2012) Involvement of the skeletal renin-angiotensin system in age-related osteoporosis of ageing mice. Biosci Biotechnol Biochem 76:1367–1371CrossRefPubMed
18.
Gu SS, Zhang Y, Wu SY, Diao TY, Gebru YA, Deng H (2012) Early molecular responses of bone to obstructive nephropathy induced by unilateral ureteral obstruction in mice. Nephrology 17:767–773CrossRefPubMed
19.
Diao TY, Pan H, Gu SS, Chen X, Zhang FY, Wong MS, Zhang Y (2014) Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. J Bone Miner Metab 32:261–270CrossRefPubMed
20.
Garcia P, Schwenzer S, Slotta JE, Scheuer C, Tami AE, Holstein JH, Histing T, Burkhardt M, Pohlemann T, Menger MD (2010) Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation—role of a local renin-angiotensin system. Br J Pharmacol 159:1672–1680CrossRefPubMedPubMedCentral
21.
Zhang Y, Wang K, Song Q, Liu R, Ji W, Ji L, Wang C (2014) Role of the local bone renin-angiotensin system in steroid-induced osteonecrosis in rabbits. Mol Med Rep 9:1128–1134PubMed
22.
Liu YY, Yao WM, Wu T, Xu BL, Chen F, Cui L (2011) Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab 29:149–158CrossRefPubMed
23.
Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, Fukagawa M, Kazama JJ, Narita I, Fukuhara S (2015) Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS One 10:e0122691CrossRefPubMedPubMedCentral
24.
Shimizu H, Nakagami H, Osako MK, Nakagami F, Kunugiza Y, Tomita T, Yoshikawa H, Rakugi H, Ogihara T, Morishita R (2009) Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens Res 32:786–790CrossRefPubMed
25.
Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, Karayalcin B, Oguz N (2012) Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep 64:878–888CrossRefPubMed
26.
Kang KY, Kang Y, Kim M, Kim Y, Yi H, Kim J, Jung HR, Park SH, Kim HY, Ju JH, Hong YS (2013) The effects of antihypertensive drugs on bone mineral density in ovariectomized mice. J Korean Med Sci 28:1139–1144CrossRefPubMedPubMedCentral
27.
28.
Ghosh M, Majumdar SR (2014) Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis. Endocrine 46:397–405CrossRefPubMed
29.
Zhang Y, Dong XL, Leung PC, Wong MS (2009) Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet. Bone 44:46–52CrossRefPubMed
30.
Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O’Brien E, Stanton A, Bedigian MP (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308:698–705CrossRefPubMed
31.
Persson F, Rossing P, Parving HH (2013) Direct renin inhibition in chronic kidney disease. Br J Clin Pharmacol 76:580–586PubMed
32.
Zhang Y, Wang Y, Chen Y, Deb DK, Sun T, Zhao Q, Li YC (2012) Inhibition of renin activity by aliskiren ameliorates diabetic nephropathy in type 1 diabetes mouse model. J Diabetes Mellitus 2:353–360CrossRef
33.
34.
Gandhi S, Srinivasan B, Akarte AS (2013) Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats. J Renin-Angiotensin Aldosterone Syst 14:3–13CrossRefPubMed
35.
Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39:E1–E8CrossRefPubMed
36.
Koid SS, Ziogas J, Campbell DJ (2014) Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism. Hypertension 63:768–773CrossRefPubMed
37.
Desjarlais M, Dussault S, Dhahri W, Mathieu R, Rivard A (2015) Direct renin inhibition with aliskiren improves ischemia-induced neovascularization: blood pressure-independent effect. Atherosclerosis 242:450–460CrossRefPubMed
38.
Yong QC, Thomas CM, Seqqat R, Chandel N, Baker KM, Kumar R (2013) Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors. Cardiovasc Diabetol 12:169CrossRefPubMedPubMedCentral
39.
Moriya H, Kobayashi S, Ohtake T, Tutumi D, Mochida Y, Ishioka K, Oka M, Maesato K, Hidaka S, Nomura S (2013) Aliskiren, a direct renin inhibitor, improves vascular endothelial function in patients on hemodialysis independent of antihypertensive effect—a pilot study. Kidney Blood Press Res 37:190–198CrossRefPubMed
40.
Li YC (2007) Inhibition of renin: an updated review of the development of renin inhibitors. Curr Opin Investig Drugs 8:750–757PubMed
41.
Zhang YF, Qin L, Leung PC, Kwok TC (2012) The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese. J Bone Miner Metab 30:666–673CrossRefPubMed
42.
Zhang Y, Diao TY, Gu SS, Wu SY, Gebru YA, Chen X, Wang JY, Ran S, Wong MS (2014) Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin. J Renin-Angiotensin Aldosterone Syst 15:218–227CrossRefPubMed
43.
Stimpel M, Jee WS, Ma Y, Yamamoto N, Chen Y (1995) Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor Moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. J Hypertens 13:1852–1856CrossRefPubMed
44.
Kwok T, Leung J, Zhang YF, Bauer D, Ensrud KE, Barrett-Connor E, Leung PC, Osteoporotic Fractures in Men (MrOS) Research Group (2012) Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos Int 23:2159–2167CrossRefPubMed
45.
Masunari N, Fujiwara S, Nakata Y, Furukawa K, Kasagi F (2008) Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci 57:17–25PubMed
46.
Kim KR, Kim HJ, Lee SK, Ma GT, Park KK, Chung WY (2015) 15-deoxy-δ12,14-prostaglandin j2 inhibits Osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss. PLoS One 10:e0122764CrossRefPubMedPubMedCentral
47.
Li Y, Shen GS, Yu C, Li GF, Shen JK, Xu YJ, Gong JP (2015) Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat. Int J Clin Exp Pathol 8:1604–1612PubMedPubMedCentral
48.
49.
Yayama K, Okamoto H (2008) Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 8:312–318CrossRefPubMed
50.
Horiuchi M, Iwanami J, Mogi M (2012) Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci (Lond) 123:193–203CrossRef
51.
Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T (2014) AT (2) receptor and tissue injury: therapeutic implications. Curr Hypertens Rep 16:416CrossRefPubMedPubMedCentral
52.
Souza PP, Brechter AB, Reis RI, Costa CA, Lundberg P, Lerner UH (2013) IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol 169:400–412CrossRefPubMedPubMedCentral
53.
Srivastava S, Sharma K, Kumar N, Roy P (2014) Bradykinin regulates osteoblast differentiation by Akt/ERK/NFκB signaling axis. J Cell Physiol 229:2088–2105CrossRefPubMed
Metadata
Title
Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice
Authors
Y. Zhang
L. Wang
Y. Song
X. Zhao
M. S. Wong
W. Zhang
Publication date
01-03-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 3/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3348-y

Other articles of this Issue 3/2016

Osteoporosis International 3/2016 Go to the issue

Original Article

Risk factors for hip fracture in very old people: a population-based study

Original Article

New method for point-of-care osteoporosis screening and diagnostics

Short Communication

Increased sclerostin and preadipocyte factor-1 levels in prepubertal rhythmic gymnasts: associations with bone mineral density, body composition, and adipocytokine values

Original Article

Serum 25-hydroxyvitamin D concentration and its determinants in the very old: the Newcastle 85+ Study

Original Article

The effects of state-level expenditures for home- and community-based services on the risk of becoming a long-stay nursing home resident after hip fracture

Original Article

Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture